MSMilan 2023 Roche calendar

	11 October Wednesday	12 October Thursday	13 October Friday
08:00	^{All day} Roche Exhibit booth A08	^{All day} Shift.ms/Roche booth D50
09:00	^{All day} ePoster: 15 ePosters MS NMOSD		^{9:35- 9:55} Product theater (Chugai): How satralizumab changed treatment strategy of NMOSD NMOSD
10:00
11:00		^{11:05 - 11:25} Booth talks: MS/NMOSD differential diagnostic & high-quality cell-based assay MS NMOSD
12:00	^{12:45 - 13:05} Booth talks: Early use of high-efficacy therapies: What is holding us back? MS		^{12:35 - 12:42} Disease activity during pre-conception, pregnancy and postpartum in women with MS receiving ocrelizumab or other disease-modifying therapies in a real-world cohort MS
13:00		^{13:10 - 13:25} Booth talks: Managing and maintaining health in MS: the MS innovation challenge MS ^{13:45 - 14:45} Symposia: If time is brain, then it is time for change: Disability prevention in MS MS
14:00			^{14:15 - 15:15} Symposia: The future is now: Paving the path for precision in neuroimmunology NI
15:00
16:00	^{16:10 - 16:40} Booth talks: Tiptoe if you must, but take a step: Brain Health in clinical practice NI ^{16:10 - 16:40} Brain exchange: Not all it seems? Following the clues in neuroimmunology NI ^{16:30 - 18:30} Poster Session 1 16 Poster MS	^{16:40 - 17:10} Brain exchange: Solving for the unknown in MS: Research and treatment in underserved populations MS	^{16:03 - 16:10} Cerebrospinal fluid and MRI analyses of fenebrutinib treatment in multiple sclerosis reveal brain penetration and early reduction of new lesion activity: Results from the phase II FENopta study MS
17:00		^{17:20 - 17:50} Brain exchange: Future of MS care: How will biomarkers be used in clinical practice? MS ^{17:00 - 19:00} Poster Session 2 11 Poster MS
18:00
19:00

Event type:

Exhibit booth

ePoster

Symposia

Product Theater (Chugai)

Booth talks

Brain exchange

Poster

Oral

Patient/Community booth

Disease area:

MS = Multiple sclerosis

NI = Neuroimmunology

NMOSD= Neuromyelitis optica spectrum disorder

M-XX-00014517

Friday, 13 October 2023, 9:35-9:55 CEST

Product theater (Chugai)

Title: How satralizumab changed treatment strategy of NMOSD
Speaker: Prof. Kazuo Fujihara

Short description:
This product theater will discuss how satralizumab changed treatment strategy of NMOSD.

ePoster

P1460 | Immune-signatures associated with ocrelizumab treatment in early relapsing-remitting MS: New data on T Cell function and pro/anti-inflammatory monocytes of the 12-month interim analysis from the MA30143 phase IIIb (ENSEMBLE) substudy
P1181 | Utility and implementation of a federated research infrastructure to assess lack of disease stability as a real-world surrogate of PIRA, by combining MS clinical trial and real-world cohort data (the INTONATE MS Consortium)
P1036 | Satralizumab treatment in adults with AQP4-IgG–seropositive neuromyelitis optica spectrum disorder: A retrospective case series
P1014 | Addressing the burdens of neuromyelitis optica spectrum disorder amid challenges of the COVID-19 pandemic: Real-world perspectives from patients
P1557 | Relapse under the prescription of satralizumab in neuromyelitis optica spectrum disorder: Analysis of a Japanese claims database
P1574 | Use of immunosuppressive therapy among patients with NMOSD using satralizumab treatment: A study based on Japanese real-world data
P1160 | Impact of ocrelizumab on patient-reported fatigue and quality of life in patients with relapsing multiple sclerosis in a real world setting: First interim analysis of the observational study MoOzaRt
P790 | Drug combination discovery for treatment of multiple sclerosis using machine learning
P1189 | Disease-related knowledge and patient perceptions in relapsing-remitting multiple sclerosis
P1190 | Development of a self-assessment tool for the autonomy of patients with multiple sclerosis (MS)
P1447 | A deep-learning based quality assessment of real-world brain MRI for multiple sclerosis
P1168 | Indicators of disease activity in people with MS treated with DMTs for mild/moderate MS: Time to escalation
P1177 | Indicators of disease activity in people with MS after escalation from DMT of mild/moderate efficacy to DMT of high efficacy
P1423 | Linguistic features identify MS-related early cognitive impairment in narrative speech
P1594 | MS patients treated with ocrelizumab using BRISA - an MS specific app in Germany

Thursday, 12 October 2023, 11:05-11:25 CEST

Booth Talks

Title: MS/NMOSD differential diagnostic & high-quality cell-based assay
Speaker: Dr Dominik Jaeger

Short description:
In this session, we will discuss a high-quality cell-based assay and its use in the differential diagnosis of NMOSD and MS.

Wednesday, 11 October 2023, 12:45-13:05 CEST

Booth Talks

Title: Early use of high-efficacy therapies: What is holding us back?
Speaker: Dr Wallace Brownlee

Short description:
In this interactive session, we will address common barriers to timely high-efficacy therapy through a case-based dialogue. Dr Brownlee will share his reflections on how to overcome barriers to optimal treatment strategy, and invite you to participate in a discussion on evolving the treatment paradigm.

Friday, 13 October 2023, 12:35-12:42 CEST

Title: Disease activity during pre-conception, pregnancy and postpartum in women with MS receiving ocrelizumab or other disease-modifying therapies in a real-world cohort
Speaker: W Yeh

Thursday, 12 October 2023, 13:10-13:25 CEST

Booth Talks

Title: Managing and maintaining health in MS: the MS innovation challenge
Speakers: Dr Vera Zingler, Dr Mark Cabatingan

Short description:
Join us to learn about the Roche/Genentech MS Innovation Challenge and how you can participate in the challenge.

Thursday, 12 October 2023, 13:45-14:45 CEST

Symposia

Title: If time is brain, then it is time for change: Disability prevention in MS
Speakers: Prof. Massimo Filippi, Dr Leorah Freeman, Dr Wallace Brownlee, Dr Riley Bove

Short description:
Discussions will focus on treatment strategies that aim to prevent disability and maximise quality of life in people with MS. The expert panel will deliver an interactive session by exploring patient case studies together with the audience, considering how challenges to timely therapy can be overcome and discussing the impact of an evolving therapeutic landscape.

Friday, 13 October 2023, 14:15-15:15 CEST

Symposia

Title: The future is now: Paving the path for precision in neuroimmunology
Speakers: Prof. Amit Bar-Or, Prof. Jacqueline Palace, Prof. Sarah Morrow

Short description:
The expert panel will explore what steps can be taken to achieve greater precision and personalisation in the care of neuroimmunological diseases. This session will cover how innovations in fluid and digital biomarkers, as well as imaging innovations, may help with diagnosis and monitoring of disease activity now and in the future.

Wednesday, 11 October 2023, 16:10-16:40 CEST

Booth Talks

Title: Tiptoe if you must, but take a step: Brain Health in clinical practice
Speakers: Dr Agne Straukiene, Matthias Fuchs

Short description:
In this fireside conversation, Dr Agne Straukiene (neurologist) and Matthias Fuchs (patient advocate) reflect on practical steps towards a holistic approach to brain health in clinical practice. They will invite you to participate in the dialogue, and share practical tips on small changes that can make a large impact on patients and their families.

Wednesday, 11 October 2023, 16:10-16:40 CEST

Brain exchange

Title: Not all it seems? Following the clues in Neuroimmunology
Moderators: Dr Matteo Gastaldi, Dr Roberto Furlan
Co-moderator: Dr Ivana Vodopivec

Short description:
This session will open with a brief case of clinical demyelination and a discussion of the diffential diagnosis. The presenters will then co-lead a discussion on the underlying mehanism of disease (e.g. pathologic auto-antibodies) and the links to the diagnostic testing and interpretation. This session will primarily discuss NMOSD and MOGAD.

Wednesday, 11 October 2023, 16:30-18:30 CEST

Poster Session 1

P241 | Cerebrospinal fluid neurofilament heavy levels correlate with spinal cord lesions and disability in multiple sclerosis
P302 | The patient impact of 10 years of ocrelizumab treatment in multiple sclerosis: Long-term data from the phase III OPERA and ORATORIO studies
P304 | Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis
P061 | Pregnancy and infant outcomes in women receiving OCR for the treatment of multiple sclerosis: Analysis of the largest available outcome database
P258 | Combining measures from clinical assessments, imaging and fluid biomarkers at one year to predict MS progression at two years
P034 | Ocrelizumab dose selection for treatment of paediatric relapsing-remitting multiple sclerosis: Updated preliminary pharmacokinetic, safety and efficacy results from the OPERETTA 1 study
P283 | Composite confirmed disability worsening is a useful clinical trial endpoint for multiple sclerosis focusing on disability progression
P100 | Smartphone-based passive monitoring of gait in people with progressive multiple sclerosis
P301 | Infection in NMOSD: An analysis of the patterns of infection in SAkuraMoon (an open-label study to evaluate the long-term safety and efficacy of satralizumab) with postmarketing data and US-based health claims data
P362 | Long-term efficacy of satralizumab in patients with aquaporin-4-IgG-seropositive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD): Results from the roll-over, open-label study SAkuraMoon
P115 | Clarification of blood-retinal barrier on AQP4-peptide immunized mice
P366 | Real-world effectiveness of ocrelizumab in patients with primary progressive multiple sclerosis grouped by EDSS at baseline – a CONFIDENCE study interim analysis
P333 | Real-world safety data from up to 4.5 years of ocrelizumab in relapsing and primary progressive multiple sclerosis - a CONFIDENCE interim analysis
P334 | Ocrelizumab safety under real-world conditions: Contrasting investigator-reported safety with patient-reported safety in people with multiple sclerosis (CONFIDENCE, COMPASS and TrotzMS)
P731 | Subcutaneous ocrelizumab in patients with multiple sclerosis: Results of the phase Ib dose-finding OCARINA I study
P370 | Subcutaneous ocrelizumab in patients with multiple sclerosis: Results of the phase III OCARINA II study

Thursday, 12 October 2023, 16:40-17:10 CEST

Brain exchange

Title: Solving for the unknown in MS: Research and treatment in underserved populations
Speakers: Dr Lilyana Amezcua, Dr Juan Acosta, Roxy Murray

Short description:
In this interactive session, Dr Liliana Amezcua (neurologist) and Roxy Murray (patient advocate) will discuss endeavours to study MS in underserved populations, and reflect on how learnings from studies could be implemented in clinical practice.

Friday, 13 October 2023, 16:03-16:10 CEST

Title: Cerebrospinal fluid and MRI analyses of fenebrutinib treatment in multiple sclerosis reveal brain penetration and early reduction of new lesion activity: Results from the phase II FENopta study
Speaker: Prof. Amit Bar-Or

Thursday, 12 October 2023, 17:20-17:50 CEST

Brain exchange

Title: Future of MS care: How will biomarkers be used in clinical practice?
Speakers: Dr Jiwon Oh, Dr Paul Giacomini, Dr Jens Wurfel, Dr James Overell

Short description:
In this session, our expert faculty will invite you to join a dialogue to envision a future care journey in MS, where tools such fluid biomarkers, digital assessments and automated MRI are integrated in a signal-driven approach to patient management.

Thursday, 12 October 2023, 17:00-19:00 CEST

Poster Session 2

P653 | Reduction of intrathecal immunoglobulin levels with ocrelizumab treatment in relapsing and primary progressive multiple sclerosis
P688 | Low disability accumulation after 4-year ocrelizumab therapy in treatment-naive patients with early-stage relapsing-remitting multiple sclerosis; sata from the phase IIIb ENSEMBLE study
P691 | One-year analysis of efficacy and safety data from Black and Hispanic patients with relapsing multiple sclerosis receiving ocrelizumab treatment in the CHIMES trial
P732 | Persistence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in the German NeuroTransData Registry
P686 | Fenebrutinib, a noncovalent, reversible, Bruton’s tyrosine kinase inhibitor, potently blocks neuroinflammation induced by Fcγ receptor activation in human microglial systems: Implications for MS treatment
P738 | Specific unmet medical needs in the care of patients with relapsing multiple sclerosis: Final results from the PROFILE RMS study
P478 | Implications of progression independent of relapse activity (PIRA) for multiple sclerosis clinical trials: Item banks could provide the precise patient-reported outcome measures needed
P484 | Relapse activity after vaccination against COVID-19 in people with multiple sclerosis: 1-year follow-up results from a nationwide longitudinal observational study
P762 | Unsupervised analysis reveals that memory IgA B cells are spared by ocrelizumab treatment
P787 | Analysis of the adaptive immune receptor repertoire alongside treatment with ocrelizumab suggests clinical relevance of B-cell repopulation versus reconstruction
P788 | Kinetic of T cell reactivity and antibody responses to SARS-CoV-2 after different rounds of vaccination in persons with multiple sclerosis treated with ocrelizumab